<DOC>
	<DOCNO>NCT02911844</DOCNO>
	<brief_summary>The main purpose clinical trial examine feasibility effect fulvestrant post-menopausal woman pulmonary arterial hypertension ( PAH ) . The study evaluate well drug tolerate . The study evaluate change circulate hematopoietic progenitor cell , plasma hormone level , NT-proBNP , plasma biomarkers administration fulvestrant . Changes tricuspid annular plane systolic excursion , stroke volume index , right ventricular fractional area change , echo parameter fulvestrant administration evaluate well change distance walk six minute .</brief_summary>
	<brief_title>Estrogen Receptor Antagonist Patients With Pulmonary Arterial Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<mesh_term>Fulvestrant</mesh_term>
	<mesh_term>Estrogen Receptor Antagonists</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Estrogens</mesh_term>
	<criteria>Previous documentation mean pulmonary artery pressure &gt; 25 mm Hg pulmonary capillary wedge pressure ( left ventricular enddiastolic pressure ) &lt; 16 mm Hg pulmonary vascular resistance &gt; 3 WU time study entry . Diagnosis PAH idiopathic , heritable , drug toxininduced , associate connective tissue disease , congenital heart disease , portal hypertension , HIV infection . Most recent pulmonary function test FEV1/FVC &gt; 50 % AND either ) total lung capacity &gt; 70 % predict b ) total lung capacity 60 % 70 % predict mild interstitial lung disease computerize tomography scan chest . Female , postmenopausal state , define : &gt; 50 year old ) menstruate precede 12 month b ) folliclestimulating hormone ( FSH ) level &gt; 40 IU/L &lt; 50 year FSH &gt; 40 IU/L bilateral oophorectomy . Informed consent . Age &lt; 18 . Treatment estrogen antihormone therapy ( tamoxifen , anastrozole , etc . ) WHO Class IV functional status . History breast cancer . Clinically significant untreated sleep apnea . Leftsided valvular disease ( moderate mitral valve stenosis insufficiency aortic stenosis insufficiency ) , pulmonary artery valve stenosis , ejection fraction &lt; 45 % echocardiography . Initiation PAH therapy ( prostacyclin analogue receptor agonist , endothelin1 receptor antagonist , phosphodiesterase5 inhibitor , soluble guanylate cyclase stimulators ) within three month enrollment ; dose must stable least 3 month prior Baseline Visit . PAH therapy stop restart dose change relate initiation uptitration allow within 3 month prior Baseline Visit . Hormone therapy . Use warfarin anticoagulant ( use aspirin permit ) . Platelet count &lt; 100,000 . Renal failure ( creatinine &gt; /= 2.0 ) . ChildPugh Class C cirrhosis . Current recent ( &lt; 6 month ) chronic heavy alcohol consumption . Current use another investigational drug ( nonFDA approve ) PAH .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>